Taysha Gene Therapies Launches with $30 Million Seed Financing and Unrivaled Strategic Partnership with the UT Southwestern Gene Therapy Program
Apr 29, 2020•about 5 years ago
Amount Raised
$30 Million
Round Type
seed
Description
Taysha Gene Therapies today announced it has launched with a mission to eradicate severe and life-threatening monogenic diseases of the central nervous system (CNS) by advancing its pipeline of 15 AAV (adeno-associated virus) gene therapy programs, with options to an additional four programs. The company reunites former investors and executives from AveXis, while accelerating its discovery and development efforts with the UT Southwestern Gene Therapy Program and Department of Pediatrics, one of the largest pediatric neurology residency programs in the U.S.
FundzWatch™ Score
74
Medium Activity
Buyer Intent Analysis
Get personalized insights on buying likelihood
Funding Insights
Based on industry dataTech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech